ENTREPRENEURIAL WORKFORCE
to enrich the biomedical innovation pipeline.
The Value of Diversity in Biomedical Innovation
NIH values the breadth of varied perspectives that comes from having a pool of highly talented scientists from diverse backgrounds, including women, members of racial and/or ethnic minority groups, people with disabilities, and those from disadvantaged and rural population centers.
Not only is NIH committed to diversifying the national scientific workforce, but SEED actively seeks diverse perspectives to enrich the biomedical innovation pipeline. With more than $1.2 billion in annual funding and ongoing entrepreneurial education and commercialization support, SEED programs empower companies to flourish throughout the evolution of their technology and company and to leverage the unique perspectives brought to bear by diverse individuals.
If you’re developing an early-stage product or service that has the potential to improve human health or conducting biomedical research, you have a place here.
Resources Available to Entrepreneurs from Underrepresented Groups:
- A free Applicant Assistance Program to help entrepreneurs that are new to the NIH Small Business Programs submit a competitive Phase I SBIR or STTR application
- The National Institute on Minority Health and Health Disparities has a free Health Disparities Pre Application (HDPreApp) Program that aims to improve an application's scientific merit and commercialization plan.
- The opportunity for current awardees to obtain additional funding through a Diversity Supplement if their small business is committed to increasing the participation of women and socially and economically disadvantaged individuals
- Presentations and guidance on the application process, SBIR/STTR basics, and more from "Diverse Perspectives SEEDing Impactful Innovations," the 2020 HHS Small Business Conference focused on introducing the Small Business Programs to underrepresented groups
Financial support from the NIH as part of their SBIR program was very much a critical component to the early start of this company [and] it continues to be a component of our success.
The NIH SBIR program has been invaluable. There'd be no other way that this would have been an option to provide to the autism community.
[The SBIRs] have allowed us to pursue new ideas and approaches to solving this long-standing problem of organ shortage.
Litron Laboratories’ rate of innovation would not be possible without the benefit of SBIR funding.
The SBIR program is significantly important for disseminating, not just information, but actual interventions, especially for underrepresented populations.
[NIH small business funding] gave us the preliminary data that allowed us to approach investors and Big Pharma to fund the amount needed to move into phase two and phase three.
The grant gave us the funding to hire curriculum writers, to pay teachers to do pilot testing of the kits, and to go to science education conferences and present the kits; it gave us money to pay stipends for teachers who wanted to hold their own workshops, and money to provide the kits for the workshop. It really allowed the company to grow much more dramatically.
[SBIR] funding was absolutely critical to getting us off the ground.
Our very first funding came from the NIH. The origins of our success came from an NIH-funded project, and since then, we have been able to build on and expand our knowledge and tackle other pollutants.
We’re staunch supporters of this program. If anyone asks me about the NIH Small Business program, I give them nothing but encouragement to apply.
[SBIR] has been a long, trying, but worthwhile journey...from multiple submissions that were not discussed...to applications that scored below the funding levels...to concurrent applications (one Phase II and a Phase I) emerging from the rigorous peer review process with impact scores in the “Excellent" range.
We were awarded a $1.5 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke in 2018. That grant came at a time when follow-on funding was uncertain, and it allowed us to accelerate the development process and cover critical commercialization costs for our novel, bioabsorbable surgical clip. We’ve since focused our energy and resources on bringing this technology to market sooner, which will ultimately benefit patients and improve public health.
I would love to see more Native American representation in the SBIR program. Including entrepreneurs from different backgrounds is key to solving “unsolvable” problems and is critical to forging new paths in science and healthcare.
In terms of venture capitalists for minority businesses, it is a really unfair playing field. So, the fact that SBIR funds minority businesses like ours is huge because otherwise, we would not get any investments.
This funding allowed me to achieve a scientific breakthrough and now I can talk about early detection, and I can talk about cancer, fibrosis, and changing the industry.
